AAPG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Ascentage Pharma Group International (AAPG) is not a strong buy at the moment given the user's long-term investment strategy and beginner level. The technical indicators show a bearish trend, and there are no immediate positive trading signals or catalysts to suggest a compelling entry point. While the company has promising long-term prospects with its pipeline assets and positive analyst ratings, the recent financial performance and market sentiment do not support an immediate buy decision.
The stock is currently in a bearish trend with the MACD histogram below zero and negatively expanding, RSI at 38.353 in the neutral zone, and bearish moving averages (SMA_200 > SMA_20 > SMA_5). The stock closed at $21.3, below the pivot level of $22.266, with key support at $20.016 and resistance at $24.516.
Analyst Jeet Mukherjee initiated coverage with a Buy rating and a $48 price target, citing the potential of Olverembatinib and Lisaftoclax in Phase 3 programs. Product sales grew 90% year-over-year in FY 2025, driven by strong sales of these key assets.
Technical indicators are bearish, and there are no significant trading trends from hedge funds or insiders.
Ascentage Pharma reported FY 2025 GAAP EPS of $0.50, exceeding expectations despite a 38.9% revenue decline to $82.1 million. However, product sales and commercial rights revenues grew 90% year-over-year, showing strong performance in specific areas.
BTIG analyst Jeet Mukherjee initiated coverage with a Buy rating and a $48 price target, citing the company's global relevance and promising pipeline assets. No recent changes in price targets or ratings were noted.
